In fiscal 2026, which ended Jun 30, 2026, Ibio, Inc. used $23.2 million of cash from operations, down 51.7% from the year before. It spent $578,000 on capital expenditures. Free cash flow was negative, at -$23.8 million.
USD in millions, except per-share amounts and ratios. The percent under a figure is the change from the year before.
| Line |
FY 2026
Jun 30, 2026
|
FY 2025
Jun 30, 2025
|
FY 2024
Jun 30, 2024
|
FY 2023
Jun 30, 2023
|
FY 2022
Jun 30, 2022
|
FY 2021
Jun 30, 2021
|
FY 2020
Jun 30, 2020
|
FY 2019
Jun 30, 2019
|
FY 2018
Jun 30, 2018
|
FY 2013
Jun 30, 2013
|
|---|---|---|---|---|---|---|---|---|---|---|
| Operating | ||||||||||
| Depreciation and amortization |
1
+15.3%
|
0
-24.1%
|
1
-5.3%
|
1
-70.4%
|
2
+382.0%
|
0
+67.4%
|
0
-80.2%
|
1
+4.3%
|
1
+3.2%
|
0
-99.4%
|
| Stock-based compensation |
1
-10.3%
|
2
-24.9%
|
2
-53.6%
|
4
+0.3%
|
4
+176.0%
|
2
+308.8%
|
0
+61.0%
|
0
-68.7%
|
1
-23.8%
|
1
-52.9%
|
| Operating cash flow |
-23
-51.7%
|
-15
+17.5%
|
-19
+39.0%
|
-30
+18.8%
|
-37
-24.7%
|
-30
-125.3%
|
-13
+4.5%
|
-14
-3.7%
|
-13
|
-5
+19.3%
|
| Investing | ||||||||||
| Capital expenditures |
1
+3512.5%
|
0
-92.4%
|
0
-96.3%
|
6
-21.7%
|
7
+49.0%
|
5
+356.4%
|
1
+17.2%
|
1
-1.5%
|
1
-29.4%
|
0
+600.0%
|
| Investing cash flow |
-32
-4412.5%
|
1
-18.1%
|
1
-87.1%
|
7
+236.7%
|
-5
+80.6%
|
-26
-2194.5%
|
-1
-16.6%
|
-1
+8.2%
|
-1
|
-0
+20.4%
|
| Financing | ||||||||||
| Financing cash flow |
103
+1054.1%
|
9
-63.5%
|
24
+964.5%
|
2
+137.6%
|
-6
-107.8%
|
79
+20.9%
|
65
+1788.0%
|
3
-84.6%
|
22
|
4
-57.6%
|
| Change in cash | ||||||||||
| Effect of exchange rate |
—
|
—
|
—
|
—
|
—
|
-0
+50.0%
|
-0
-100.0%
|
-0
+0.0%
|
-0
|
—
|
| Net change in cash |
48
+949.1%
|
-6
-182.3%
|
7
+132.5%
|
-21
+56.7%
|
-49
-318.6%
|
22
-56.0%
|
51
+540.3%
|
-12
|
—
|
—
|
| Free cash flow |
-24
-55.3%
|
-15
+18.4%
|
-19
+48.1%
|
-36
+19.3%
|
-45
-28.1%
|
-35
-142.6%
|
-14
+3.2%
|
-15
-3.3%
|
-14
|
-5
+19.2%
|
| Per share | ||||||||||
| Free cash flow per share |
-0.23
+84.3%
|
-1.46
+70.2%
|
-4.90
+91.7%
|
-59.11
-1050.4%
|
-5.14
|
—
|
—
|
—
|
—
|
—
|
| Ratios | ||||||||||
| Free cash flow margin |
-23,796.00%
|
-3,830.00%
|
-8,339.56%
|
—
|
-2,378.45%
|
-1,475.50%
|
-880.53%
|
-40,256.76%
|
-3,246.40%
|
-482.22%
|
| Capital expenditures to revenue |
578.00%
|
4.00%
|
93.33%
|
—
|
389.07%
|
207.51%
|
65.81%
|
2,486.49%
|
210.36%
|
0.70%
|
| Stock-based compensation to revenue |
1,373.00%
|
382.50%
|
905.78%
|
—
|
232.32%
|
66.89%
|
23.69%
|
651.35%
|
173.42%
|
125.42%
|
How these figures are calculated
Annual columns are full-year amounts from the annual report (Form 10-K, 20-F, or 40-F). If a company restates a year, the latest filed number is shown. USD in millions, except per-share amounts and ratios. Capital expenditures, debt repaid, dividends, and buybacks are positive amounts. Investing and financing cash flow keep the filing sign, so an outflow is negative. Free cash flow is operating cash flow minus capital expenditures. Returned to shareholders is dividends plus buybacks. Free cash flow margin, capital expenditures, and stock-based compensation are divided by revenue. Cash conversion is operating cash flow divided by net income. More on our methodology.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- IBIO (Nasdaq)
- Fiscal year ends
- June 30
- Incorporated in
- DE
- Headquarters
- New York, NY
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1420720
- Former names
- iBio, Inc. (until Oct 19, 2026); iBioPharma, Inc. (until Aug 14, 2009); InB:Biotechnologies, Inc. (until Jul 17, 2008)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.